Mainz Biomed B.V.
MYNZ · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -147.00% | -217.07% | -107.12% | -23.97% |
| EV / EBITDA | -0.73 | -0.12 | -1.58 | -1.65 |
| Quality | ||||
| ROIC | -139.30% | -91.69% | -209.43% | -107.32% |
| Gross Margin | -108.24% | 68.55% | 61.26% | 18.74% |
| Cash Conversion Ratio | 0.78 | 0.84 | 0.74 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.46% | 36.38% | 56.57% | 106.83% |
| Free Cash Flow Growth | 28.22% | -9.85% | -68.10% | 6.21% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | 0.29 | -0.77 | -0.03 |
| Interest Coverage | -37.59 | -8.27 | -14.87 | -18.45 |
| Efficiency | ||||
| Inventory Turnover | 1.19 | 0.31 | 0.39 | 0.27 |
| Cash Conversion Cycle | 47.99 | -624.24 | -481.13 | -794.30 |